Hillevax Inc

NASDAQ HLVX

Data sourced from

and

Download Data

Hillevax Inc Cash Return on Assets (CROA) for the quarter ending March 31, 2024: -0.11

Hillevax Inc Cash Return on Assets (CROA) is -0.11 for the quarter ending March 31, 2024, a -98.16% change year over year. The cash return on assets ratio measures the profitability of a company's total assets based on its operating cash flow. It is calculated by dividing operating cash flow by total assets. This ratio indicates the company's ability to generate cash flow relative to its asset base. A higher ratio suggests more efficient utilization of assets in generating cash flow.

Hillevax Inc Cash Return on Assets (CROA) for the quarter ending March 31, 2023 was -0.05, a 43.26% change year over year.
Hillevax Inc Cash Return on Assets (CROA) for the quarter ending March 31, 2022 was -0.09.

NASDAQ: HLVX

Hillevax Inc

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street, Boston, MA, United States, 02109
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Key trends